Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96

Inclusion criteria

• Able to read and understand the informed consent document; must sign the informed consent.
• Aged 18 to 75 years old , sex is not limited
• Newly Diagnosed supratentoria glioma, Must have undergone a at least a 80% resection
• Availability of at least 1 g tumor sample.
• Karnofsky functional status rating > or equal to 70.
• Adequate bone marrow function including the absence of lymphopenia (ANC > 1,500/ mm3; Hemoglobin > 10g/dL ; platelet count >100,000/mm3), adequate liver function (serum glutamic oxaloacetic transaminase/ aspartate aminotransferase [AST], alanine amino transferase [ALT] <2.5 times institutional upper limit of normals [IULNs] ), and adequate renal function (BUN and creatinine <1.5 times IULNs)
• Agree to Surgical indications of Heart & lung and without the coagulation system disease
• Negative pregnancy test for female patients of childbearing potential
• Agree to use contraception or abstain from sexual activity from the time of consent through 3 month after the end of study drug administration

Exclusion criteria

• Inability to comply with study-related procedures
• patient not suitable for Neurosurgery.
• Unavailability of at least 6 doses of vaccine
• Progression prior to vaccination as determined by the Principal Investigator
• Patient with allergic constitution
• Unstable or severe intercurrent medical conditions
• Current diagnosis of Human Immunodeficiency Virus and Patients with active uncontrolled infection.
• patients with any systemic disease needed to be treated with immunosuppressant or Corticosteroids.
• any other clinical trials within 30 days pre-vaccination.
• Female patients who are pregnant or breastfeeding